

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-67618-07
Application Number	10/563,683
Filing Date	October 4, 2006
First Named Inventor	Gladwin
Art Unit	1616
Examiner Name	

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
/A.P./	1	5,485,827	1/23/1996	Zapol <i>et al.</i>
	2	5,873,359	2/23/1999	Zapol <i>et al.</i>
	3	5,994,444	11/30/1999	Trescony <i>et al.</i>
	4	6,187,744	2/13/2001	Rooney
	5	6,197,745	3/6/2001	Stamler
	6	6,291,424	9/18/2001	Stamler <i>et al.</i>
	7	6,358,536	3/19/2002	Thomas
	8	6,583,113	6/24/2003	Stamler <i>et al.</i>
	9	6,627,738	9/30/2003	Stamler <i>et al.</i>
	10	6,642,438	11/4/2003	Clendennen <i>et al.</i>
	11	6,796,966	9/28/2004	Thomas
	12	6,884,773	4/26/2005	Stamler <i>et al.</i>
	13	6,945,247	9/20/2005	Stamler <i>et al.</i>
	14	7,025,869	4/11/2006	Fine <i>et al.</i>
	15	7,033,999	4/25/2006	Stamler <i>et al.</i>
	16	7,202,340	4/10/2007	Stamler <i>et al.</i>
/A.P./	17	US2001/0034323	10/25/2001	Rooney

EXAMINER
SIGNATURE: /Anna Pagonakis/

DATE
CONSIDERED: 09/25/2008


* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


Attorney Docket Number	4239-67618-07
Application Number	10/563,683
Filing Date	October 4, 2006
First Named Inventor	Gladwin
Art Unit	1616
Examiner Name	

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
/A.P./	18	US2002/0037839	3/28/2002	Stamler <i>et al.</i>
	19	US2002/0095108	7/18/2002	Tsuchida <i>et al.</i>
	20	US2003/0022267	1/30/2003	Stamler <i>et al.</i>
	21	US2005/0227912	10/13/2005	Fronticelli <i>et al.</i>
	22	US2006/0088583	4/27/2006	Takeoka <i>et al.</i>
	23	US2006/0242671	11/9/2006	Stamler <i>et al.</i>
/A.P./	24	US2007/0167352	7/19/2007	Winslow <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
/A.P./	25	WO	96/30006	10/3/1996	Brigham and Women's Hospital
	26	WO	97/10265	3/20/1997	Duke University
	27	WO	03/102575	12/11/2003	Duke University
	28	WO	2004/054433	7/1/2004	Duke University
	29	WO	2006/113540	10/26/2006	Duke University
/A.P./	30	WO	2006/096774	9/14/2006	Sangart, Inc.

EXAMINER
SIGNATURE: /Anna Pagonakis/

DATE
CONSIDERED: 09/25/2008

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-67618-07
Application Number	10/563,683
Filing Date	October 4, 2006
First Named Inventor	Gladwin
Art Unit	1616
Examiner Name	

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
/A.P./	31	ALI <i>et al.</i> "A Method to Attenuate Pneumoperitoneum-Induced Reductions in Splanchnic Blood Flow," <i>Annals of Surgery</i> 241 (2): 256-261 (2005)
	32	ANGELO <i>et al.</i> "An S-nitrosothiol (SNO) synthase function of hemoglobin that utilizes nitrite as a substrate," <i>Proc. Natl. Acad. Sci. USA</i> 103 (33): 8366-8371 (2006)
	33	BASIREDDY <i>et al.</i> "Effects of sodium nitrite on ischemia=reperfusion injury in the rat kidney," <i>Am J Physiol Renal Physiol</i> 290: 779-786 (2005)
	34	CRAWFORD <i>et al.</i> "Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation," <i>Blood</i> 107 (2): 566-574 (2006)
	35	DURANSKI <i>et al.</i> "Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver," <i>Journal of Clinical Investigation</i> 115 (5): 1232-1240 (2005)
	36	GLADWIN, "Nitrite as an intrinsic signaling molecule," <i>Nature Chemical Biology</i> 1: 245-246 (2005)
	37	GLADWIN <i>et al.</i> "Corrigendum: The emerging biology of the nitrite anion," <i>Nature Chemical Biology</i> 2: 110 (2006)
	38	GOW <i>et al.</i> "The oxyhemoglobin reaction of nitric oxide," <i>Proc. Natl. Acad. Sci. USA</i> 96: 9027-9032 (1999)
	39	GOW and STAMLER, "Reactions between nitric oxide and haemoglobin under physiological conditions," <i>Nature</i> 391: 169-173 (1998) (Abstract Only)
	40	KIM-SHAPIO <i>et al.</i> "Unraveling the Reaction of Nitric Oxide, Nitrite, and Hemoglobin in Physiology and Therapeutics," <i>Arterioscler. Thromb. Vasc. Biol.</i> 26: 697-705 (2006)
	41	LUCHSINGER <i>et al.</i> "Routes to S-nitroso-hemoglobin formation with heme redox and preferential reactivity in the subunits," <i>Proc. Natl. Acad. Sci. USA</i> 100 (2): 461-466 (2003)
	42	MCAHON <i>et al.</i> "A nitric oxide processing defect of red blood cells created by hypoxia: Deficiency of S-nitrosohemoglobin in pulmonary hypertension," <i>Proc. Natl. Acad. Sci. USA</i> 102 (41): 14801-14806 (2005)
	43	SHIVA <i>et al.</i> "Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis," <i>Nature Chemical Biology</i> 2: 486-493 (2006)
/A.P./	44	WINSLOW, "Red Cell Substitutes," <i>Seminars in Hematology</i> 44:51-59 (2007)

EXAMINER
SIGNATURE: /Anna Pagonakis/

DATE
CONSIDERED: 09/25/2008

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.